Journal of Obesity

Pharmacologic Treatment of Obesity


Publishing date
15 Nov 2010
Status
Published
Submission deadline
15 May 2010

Lead Editor

1University of São Paulo, São Paulo, Brazil

2Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium


Pharmacologic Treatment of Obesity

Description

Obesity is a serious disease with many associated comorbidities and should be effectively treated. In many obese patients, treatment based on only lifestyle interventions may not result in desirable weight loss and the availability of effective complementary drug treatment would be desirable.

The special issue on pharmacologic treatment of obesity is now requesting submission of original research and review articles with main topics of interest including, but not limited to, animal and human studies of:

  • New central and peripheral targets
  • Mechanism of drug action
  • Pharmacogenomics
  • New biomarkers
  • New/novel experimental study designs
  • Randomized controlled clinical trials, including in selected populations
  • Comorbidity effects
  • Combination drug treatments
  • Future perspectives

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jobes/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2011
  • - Article ID 751063
  • - Editorial

Pharmacologic Treatment of Obesity

Alfredo Halpern | Steven B. Heymsfield | Luc Van Gaal
  • Special Issue
  • - Volume 2011
  • - Article ID 516842
  • - Research Article

Hepatoportal Leptin Sensors and Their Reflex Effects on Autonomic Outflow in the Rat

Akira Niijima
  • Special Issue
  • - Volume 2011
  • - Article ID 490650
  • - Review Article

Different Adipose Depots: Their Role in the Development of Metabolic Syndrome and Mitochondrial Response to Hypolipidemic Agents

Bodil Bjørndal | Lena Burri | ... | Rolf K. Berge
  • Special Issue
  • - Volume 2011
  • - Article ID 636181
  • - Review Article

Present and Future: Pharmacologic Treatment of Obesity

Mariela Glandt | Itamar Raz
  • Special Issue
  • - Volume 2011
  • - Article ID 475786
  • - Research Article

Oral Administration of Semicarbazide Limits Weight Gain together with Inhibition of Fat Deposition and of Primary Amine Oxidase Activity in Adipose Tissue

Josep Mercader | Zsuzsa Iffiú-Soltész | ... | Christian Carpéné
  • Special Issue
  • - Volume 2011
  • - Article ID 893629
  • - Review Article

Weight Gain, Obesity, and Psychotropic Prescribing

Nikhil Nihalani | Thomas L. Schwartz | ... | James L. Megna
  • Special Issue
  • - Volume 2011
  • - Article ID 946795
  • - Research Article

Serum Neopterin Is Not Increased in Obese Juveniles

Harald Mangge | Florian Freytag | ... | Dietmar Fuchs
  • Special Issue
  • - Volume 2011
  • - Article ID 957268
  • - Clinical Study

Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia

Changyu Pan | Hyung Joon Yoo | Low-Tone Ho
  • Special Issue
  • - Volume 2011
  • - Article ID 897894
  • - Review Article

Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists

Josep Bassaganya-Riera | Amir J. Guri | Raquel Hontecillas
  • Special Issue
  • - Volume 2011
  • - Article ID 394658
  • - Clinical Study

Impact of Orlistat-Induced Weight Loss on Diastolic Function and Heart Rate Variability in Severely Obese Subjects with Diabetes

Julie Martin | Carmen Paquette | ... | Paul Poirier
Journal of Obesity
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision89 days
Acceptance to publication15 days
CiteScore7.400
Journal Citation Indicator0.700
Impact Factor3.3
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.